XML 88 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1
Quarterly Financial Information (Unaudited) (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]                      
Revenue under collaborative research and development arrangements $ 7,409,214 $ 351,272 $ 16,358,316 $ 4,288,586 $ 476,586 $ 2,327,316 $ 1,889,988 $ 1,796,857 $ 28,407,388 $ 6,490,747 $ 26,876,533
Revenue under collaborative research and development arrangements with affiliated entity 226,486 129,133 176,879 233,330 189,278 574,596 499,720 137,000 765,828 1,400,594 779,167
Grants and miscellaneous revenue 980,443 1,456,216 2,797,647 5,240,233 7,735,428 9,410,648 3,814,083 6,176,298 10,474,539 27,136,457 12,916,411
Grants and miscellaneous revenue from affiliated entity 171,091 707,922 1,079,282 614,036 112,660 227,903 0 0 2,572,331 340,563 0
Total revenues 8,787,234 2,644,543 20,412,124 10,376,185 8,513,952 12,540,463 6,203,791 8,110,155 42,220,086 35,368,361 40,572,111
Research and development 24,641,124 25,510,239 23,878,751 24,542,504 23,911,731 26,980,343 19,630,801 18,189,160 98,572,618 88,712,035 57,791,923
General and administrative 8,033,899 6,319,775 6,169,106 7,767,589 6,965,517 5,755,603 5,799,530 5,371,613 28,290,369 23,892,263 18,063,890
Gain on sale of assets (1,000,000) 0 0 0 0 0 (1,000,000) 0 (1,000,000) (1,000,000) (1,000,000)
Total operating expenses 31,675,023 31,830,014 30,047,857 32,310,093 30,877,248 32,735,946 24,430,331 23,560,773 125,862,987 111,604,298 74,855,813
Loss from operations (22,887,789) (29,185,471) (9,635,733) (21,933,908) (22,363,296) (20,195,483) (18,226,540) (15,450,618) (83,642,901) (76,235,937) (34,283,702)
Interest and other income, net 509,266 463,346 300,021 340,341 191,460 391,596 341,131 333,070 1,612,974 1,257,257 305,071
Change in fair value of common stock warrants 579,546 423,296 (312,500) 116,477 644,888 2,690 (113,775) (406,249) 806,819 127,554 177,561
Gain (Loss) from investment in affiliated entity 292,798 (5,835,741) 169,096 (1,608,817) (4,706,522) (958,141) (705,527) 7,480,977 (6,982,664) 1,110,787 2,600,467
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (21,506,179) $ (34,134,570) $ (9,479,116) $ (23,085,907) $ (26,233,470) $ (20,759,338) $ (18,704,711) $ (8,042,820) $ (88,205,772) $ (73,740,339) $ (29,187,606)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders                      
Basic ($ per share) $ (0.24) $ (0.39) $ (0.13) $ (0.31) $ (0.35) $ (0.28) $ (0.26) $ (0.11) $ (1.08) $ (1.01) $ (0.43)
Diluted ($ per share) $ (0.24) $ (0.40) $ (0.13) $ (0.31) $ (0.36) $ (0.28) $ (0.26) $ (0.11) $ (1.09) $ (1.01) $ (0.44)